US2011230637A1PendingUtilityA1

Modified human thymic stromal lymphopoietin

62
Assignee: IMMUNEX CORPPriority: Jul 23, 2001Filed: Jun 1, 2011Published: Sep 22, 2011
Est. expiryJul 23, 2021(expired)· nominal 20-yr term from priority
Inventors:Stewart D. LymanKirk P. Van NessRaymond J. Paxton
C07K 2319/20G01N 2333/52A61K 38/00A61P 35/00G01N 2333/47G01N 33/6854A61P 31/12A61P 37/00A61P 31/04C07K 2319/31C07K 14/5418C07K 16/28A61P 37/04A61P 31/10A61P 43/00C07K 14/52
62
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Modified, furin resistant human TSLP polypeptides and polynucleotides encoding the modified human TSLP polypeptides are provided. Pharmaceutical compositions, B and T cell activation agents, assays and methods of use are also described.

Claims

exact text as granted — not AI-modified
1 . An isolated polypeptide comprising at least 90% amino acid sequence identity to SEQ ID NO: 4, wherein the polypeptide comprises a modification to inactivate the furin cleavage site RRKRK at position 127-131 of SEQ ID NO: 4. 
     
     
         2 . The polypeptide of  claim 1  wherein the polypeptide comprises at least 90% amino acid sequence identity to SEQ ID NO: 10. 
     
     
         3 . The polypeptide of  claim 1  wherein the polypeptide comprises at least 90% amino acid sequence identity to SEQ ID NO: 12. 
     
     
         4 . The polypeptide of  claim 1  wherein the polypeptide comprises at least 90% amino acid sequence identity to SEQ ID NO: 14. 
     
     
         5 . The polypeptide of  claim 1  wherein the polypeptide comprises at least 90% amino acid sequence identity to SEQ ID NO: 16. 
     
     
         6 . The polypeptide of  claim 1  wherein the polypeptide comprises at least 90% amino acid sequence identity to SEQ ID NO: 17. 
     
     
         7 . The polypeptide of  claim 1  wherein the polypeptide comprises at least 90% amino acid sequence identity to SEQ ID NO: 18. 
     
     
         8 . The polypeptide of  claim 2 , wherein the polypeptide comprises the amino acid sequence as set forth in SEQ ID NO:10. 
     
     
         9 . The polypeptide of  claim 3 , wherein the polypeptide comprises the amino acid sequence as set forth in SEQ ID NO:12. 
     
     
         10 . The polypeptide of  claim 4 , wherein the polypeptide comprises the amino acid sequence as set forth in SEQ ID NO:14. 
     
     
         11 . The polypeptide of  claim 5 , wherein the polypeptide comprises the amino acid sequence as set forth in SEQ ID NO:16. 
     
     
         12 . The polypeptide of  claim 6 , wherein the polypeptide comprises the amino acid sequence as set forth in SEQ ID NO:17. 
     
     
         13 . The polypeptide of  claim 7 , wherein the polypeptide comprises the amino acid sequence as set forth in SEQ ID NO:18. 
     
     
         14 . The polypeptide of  claim 1 , wherein the polypeptide has at least 95% amino acid sequence identity to SEQ ID NO: 4.

Join the waitlist — get patent alerts

Track US2011230637A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.